Literature DB >> 7124766

Serial pulmonary function in systemic sclerosis.

P D Schneider, R A Wise, M C Hochberg, F M Wigley.   

Abstract

The natural history of the pulmonary involvement in systemic sclerosis is not well studied. Reported here are the serial measurements of pulmonary function in a well defined population of patients with systemic sclerosis followed over a mean of 63 months. The mean rate of loss of vital capacity (0.10 liters per year) for the 38 patients serially studied was more than three times the expected rate of loss for a normal population. The mean rate of loss of diffusing capacity (0.33 ml/min/mm Hg per year) for the 27 patients serially studied was similar to that for a normal population. The percent forced vital capacity expired in the first second increased 0.53 percent per year consistent with a progressive restrictive ventilatory defect. Smokers tended to lose vital capacity at a slightly greater rate than nonsmokers (p = 0.069). Individual variability in the course of pulmonary function was observed. Although the overall trend in our population was towards a slowly progressive restrictive ventilatory defect, pulmonary function in the nonsmokers did not change at rates different from those in a nonsmoking reference population.

Entities:  

Mesh:

Year:  1982        PMID: 7124766     DOI: 10.1016/0002-9343(82)90732-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease.

Authors:  E Renzoni; P Rottoli; G Coviello; M G Perari; M Galeazzi; M Vagliasindi
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

2.  A longitudinal study of pulmonary function in Danish patients with systemic sclerosis.

Authors:  S Jacobsen; P Halberg; S Ullman; M Høier-Madsen; J Petersen; J Mortensen; A Wiik
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

3.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

Review 4.  Scleroderma lung: pathogenesis, evaluation and current therapy.

Authors:  Jacob M van Laar; Jan Stolk; Alan Tyndall
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis.

Authors:  Silvia A Quadrelli; Luciana Molinari; Lorena M Ciallella; Martin Bosio; Alejandro Salvado
Journal:  Rheumatol Int       Date:  2009-01-08       Impact factor: 2.631

6.  Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions.

Authors:  Paola Caramaschi; Domenico Biasi; Marcello Ferrari; Alessandro Volpe; Nicola Martinelli; Antonio Carletto; Paola Dal Forno; Lisa Maria Bambara
Journal:  Rheumatol Int       Date:  2004-02-13       Impact factor: 2.631

7.  Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger?

Authors:  M J Abramson; A J Barnett; G O Littlejohn; M M Smith; S Hall
Journal:  Postgrad Med J       Date:  1991-07       Impact factor: 2.401

8.  Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up.

Authors:  C Agustí; A Xaubet; J Roca; A G Agustí; R Rodriguez-Roisin
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

9.  Value of lung diffusing capacity for nitric oxide in systemic sclerosis.

Authors:  Giovanni Barisione; Alessandro Garlaschi; Mariaelena Occhipinti; Michele Baroffio; Massimo Pistolesi; Vito Brusasco
Journal:  Physiol Rep       Date:  2019-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.